StockData
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. (APRE) stock

APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$0.45+0.05 (+11.52%)

Close on Nov 17, 2026Market cap $5.71MP/E –Yield –

Aprea Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Aprea Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$13.20M. For fiscal 2025 it was -$13.21M. The highest annual figure on record is -$13.21M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.21M–
FY2024Dec 31, 2024-$14.30M–
FY2023Dec 31, 2023-$15.46M–
FY2022Dec 31, 2022-$113.39M–
FY2021Dec 31, 2021-$37.43M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.03M–
Q1 FY2026Mar 31, 2026-$3.42M–
Q4 FY2025Dec 31, 2025-$2.64M–
Q3 FY2025Sep 30, 2025-$3.11M–
Q2 FY2025Jun 30, 2025-$3.38M–
Q1 FY2025Mar 31, 2025-$4.08M–
Q4 FY2024Dec 31, 2024-$3.22M–
Q3 FY2024Sep 30, 2024-$4.09M–
Q2 FY2024Jun 30, 2024-$3.84M–
Q1 FY2024Mar 31, 2024-$3.14M–
Q4 FY2023Dec 31, 2023-$3.67M–
Q3 FY2023Sep 30, 2023-$3.52M–
Q2 FY2023Jun 30, 2023-$3.65M–
Q1 FY2023Mar 31, 2023-$4.62M–
Q4 FY2022Dec 31, 2022-$2.65M–
Q3 FY2022Sep 30, 2022-$4.20M–
Q2 FY2022Jun 30, 2022-$98.46M–

More Aprea Therapeutics figures

See a number that looks wrong?